Alexander Carpinteiro

Alexander Carpinteiro

Auto-generated profile, based on publicly available information

Alexander Carpinteiro

Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Blood
Verified
Journal Article
Open access
PDF file
NFNathalie Forgeard
Nathalie Forgeard
DEDikélélé Elessa
Dikélélé Elessa
ACAlexander Carpinteiro
Alexander Carpinteiro
KBKarim Belhadj
Karim Belhadj
MMMonique Minnema
Monique Minnema
BABertrand Arnulf
Bertrand Arnulf
Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate o

8 June 2023 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MPMaria Papathanasiou
Maria Papathanasiou
LKLukas Kessler
Lukas Kessler
FBFrank Bengel
Frank Bengel
AJAiste-Monika Jakstaite
Aiste-Monika Jakstaite
DKDavid Kersting
David Kersting
CRChristoph Rischpler
Christoph Rischpler
Cardiac transthyretin amyloidosis is an infiltrative cardiomyopathy with high mortality. To date, there are no specific biomarkers to directly assess disease activity and response to specific treatments. Our aim was to evaluate scintigraphic changes after treatment with the transthyretin stabilizer tafamidis. Methods: We included patients who had undergone 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy before tafamidis initiation and after at least 9 mo. Tracer activity was assessed visually and quantitatively as SUVmax. Results: The study included 14 patients who were on tafamidis for 44 ± 14 mo. We observed regression of Perugini grade in 5 patients, unchanged grade in 9 patients, and regression of mean heart–to–contralateral-lung ratio (P = 0.015) and SUVmax (P = 0.005). There were no changes in N-terminal pro-B-type natriuretic peptide or echocardiographic measures. Conclusion: Treatment with tafamidis results in regression of myocardial 99mTc-DPD uptake. 99mTc-DPD scintigraphy may provide useful imaging biomarkers to assess response to treatment. Visual Abstract

15 October 2016 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
KBKatrin Anne Becker
Katrin Anne Becker
NBNadine Beckmann
Nadine Beckmann
CAConstantin Adams
Constantin Adams
GHGabriele Hessler
Gabriele Hessler
MKMelanie Kramer
Melanie Kramer
ACAlexander Carpinteiro
Alexander Carpinteiro

4 January 2022 in Biological Psychiatry Global Open Science
Verified
Journal Article
Open access
NHNicolas Hoertel
Nicolas Hoertel
MSMarina Sánchez-Rico
Marina Sánchez-Rico
PMPedro de la Muela
Pedro de la Muela
MAMiriam Abellán
Miriam Abellán
CBCarlos Blanco
Carlos Blanco
EZEric Zapletal
Eric Zapletal
Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific psychiatric disorders are intrinsic risk factors of death in COVID-19 or whether these associations reflect the greater prevalence of medical risk factors in people with psychiatric disorders has yet to be evaluated. We performed an observational, multicenter, retrospective cohort study to examine the association between psychiatric disorders and mortality among patients hospitalized for laboratory-confirmed COVID-19 at 36 Greater Paris University hospitals. Of 15,168 adult patients, 857 (5.7%) had an ICD-10 diagnosis of psychiatric disorder. Over a mean follow-up period of 14.6 days (SD = 17.9), 326 of 857 (38.0%) patients with a diagnosis of psychiatric disorder died compared with 1276 of 14,311 (8.9%) patients without such a diagnosis (odds ratio 6.27, 95% CI 5.40–7.28, p < .01). When adjusting for age, sex, hospital, current smoking status, and medications according to compassionate use or as part of a clinical trial, this association remained significant (adjusted odds ratio 3.27, 95% CI 2.78–3.85, p < .01). However, additional adjustments for obesity and number of medical conditions resulted in a nonsignificant association (adjusted odds ratio 1.02, 95% CI 0.84–1.23, p = .86). Exploratory analyses after the same adjustments suggested that a diagnosis of mood disorders was significantly associated with reduced mortality, which might be explained by the use of antidepressants. These findings suggest that the increased risk of COVID-19–related mortality in individuals with psychiatric disorders hospitalized for COVID-19 might be explained by the greater number of medical conditions and the higher prevalence of obesity in this population and not by the underlying psychiatric disease.

10 February 2025 in Amyloid
Verified
Journal Article
Closed access
HNHironobu Naiki
Hironobu Naiki
MJMona Johnson
Mona Johnson
KWKaylee Walters
Kaylee Walters
ACAlexander Carpinteiro
Alexander Carpinteiro
MCM. Teresa Cibeira
M. Teresa Cibeira
Stefan SchönlandStefan Schönland
Stefan Schönland
Accurate tissue typing in amyloidosis is essential to provide appropriate therapy for individual patients. To get a real-life overview of typing strategies worldwide. The International Society of Amyloidosis (ISA) performed an online questionnaire survey among ISA members. We prepared questionnaire sheets for referral institutions (Category 1; C1), institutions performing amyloid typing for internal requests only (C2), and institutions outsourcing amyloid typing to referral institutions (C3), respectively. Seventy-six institutions participated in this survey, including C1 (n = 33), C2 (n = 20) and C3 (n = 23) institutions. Multiple typing methods were available across the responding institutions, including immunohistochemistry (85% of C1/C2 institutions), immunofluorescence microscopy (43%), genetic analysis (77%) and mass spectrometric analysis (42%). Commercial antibodies were used worldwide for immunohistochemistry. C1 institutions in Europe and Asia also used various in-house antibodies. Ninety-three percent of institutions performed genetic analysis of TTR gene, followed by APOA1 (43%), FGA, GSN, LYZ (33%) and APOA2 (31%). Hierarchical referral flows of mass spectrometric analysis, immunohistochemistry and genetic analysis were observed regionally and internationally. Globalization and centralization of referral flows were more prominent for mass spectrometric analysis. These data provide an assessment of the current state, enabling improvement in capabilities of amyloid typing worldwide and enhancing regional/international networks.

6 December 2019 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
TBTim Bergermann
Tim Bergermann
LBLukas Born
Lukas Born
FFFiona Ferguson
Fiona Ferguson
PLPaula Latkovic
Paula Latkovic
ASAlexandra Scheul
Alexandra Scheul
ACAlexander Carpinteiro
Alexander Carpinteiro
We have previously shown that inhibition of the mitochondrial Kv1.3 channel results in an initial mitochondrial hyperpolarization and a release of oxygen radicals that mediate mitochondrial depolarization, cytochrome c release and death. Here, we investigated whether inhibition of Kv1.3 channels can also induce cellular resistance mechanisms that counteract the induction of cell death under certain conditions. We treated leukemic T cells with the mitochondria-targeted Kv1.3 inhibitor PCARBTP and determined the activity of different kinases associated with cell survival including ZAP70, PI-3-K, AKT, JNK and ERK by measuring the activation-associated phosphorylation of these proteins. Furthermore, we inhibited AKT and JNK and determined the effect of PCARBTP-induced tumor cell death. We demonstrate that treatment of Jurkat T leukemia cells with low doses of the mitochondria-targeted inhibitor of Kv1.3 PCARBTP (0.25 μM or 1 μM) for 10 minutes induced a constitutive phosphorylation/activation of the pro-survival signaling molecules ZAP70, PI-3-K, AKT and JNK, while the phosphorylation/activation of ERK was not affected. Stimulation of Jurkat cells via the TCR/CD3 complex induced an additional activation of a similar pattern of signaling events. Higher doses of the Kv1.3 inhibitor, i.e. 10 μM PCARBTP, reduced the basal phosphorylation/activation of these signaling molecules and also impaired their activation upon stimulation via the TCR/CD3 complex. A low dose of PCARBTP, i.e. 0.25 μM PCARBTP, was almost without any effect on cell death. In contrast, concomitant inhibition of PI-3-K or AKT greatly sensitized Jurkat leukemia cells to the Kv1.3 inhibitor PCARBTP and allowed induction of cell death already at 0.25 μM PCARBTP. These studies indicate that Jurkat leukemia cells respond to low doses of the mitochondria-targeted Kv1.3 inhibitor PCARBTP with an activation of survival signals counteracting cell death. Inhibition of these T cell survival signals sensitizes leukemia cells to death induced by mitochondria-targeted Kv1.3 inhibitors. High doses of the Kv1.3 inhibitor inactivate these signals directly permitting death.